Browsing by Author "Isenberg, D"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical UsefulnessPublication . Guerreiro Castro, S; Isenberg, DSystemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
- Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus ErythematosusPublication . Carreira, P; Isenberg, DSLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.